Daunorubicin Hydrochloride – Uses, Dosage, Side Effects, Interaction Daunorubicin is an anthracycline antibiotic that has antineoplastic activity and is used in the therapy of acute leukemia and AIDS-related Kaposi sarcoma. Daunorubicin is associated with a low rate of transient serum enzyme and bilirubin elevations during therapy but has not been implicated in cases of clinically apparent acute liver injury with jaundice. Daunorubicin is an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Daunorubicin is a natural product found in Actinomadura roseola. It has a role as an antineoplastic agent and a bacterial metabolite. It is an anthracycline, a member of tetracenequinones, a member of p-quinones, and an aminoglycoside antibiotic. It is a conjugate base of daunorubicin(1+). It derives from a hydride of tetracene. Daunorubicin Hydrochloride is the hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Mechanism of Action Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Daunorubicin is an antineoplastic antibiotic. Daunorubicin has antimitotic and cytotoxic activity. Daunorubicin forms a complex with DNA by intercalation between base pairs. By stabilizing the complex between DNA and topoisomerase II, daunorubicin inhibits the activity of this enzyme, resulting in single-strand and double-strand breaks in DNA. Daunorubicin also may inhibit polymerase activity, affect regulation of gene expression, and be involved in free radical damage to DNA. Although daunorubicin is maximally cytotoxic in the S phase, the drug is not cycle-phase specific. Daunorubicin also has antibacterial and immunosuppressive properties. or Anthracyclines are an important reagent in many chemotherapy regimes for treating a wide range of tumors. One of the primary mechanisms of anthracycline action involves DNA damage caused by inhibition of topoisomerase II. Enzymatic detoxification of anthracycline is a major critical factor that determines anthracycline resistance. Natural product, daunorubicin a toxic analogue of anthracycline is reduced to less toxic daunorubicinol by the AKR1B10, enzyme, which is overexpressed in most cases of smoking associate squamous cell carcinoma (SCC) and adenocarcinoma. In addition, AKR1B10 was discovered as an enzyme overexpressed in human liver, cervical and endometrial cancer cases in samples from uterine cancer patients. Also, the expression of AKR1B10 was associated with tumor recurrence after surgery and keratinization of squamous cell carcinoma in cervical cancer and estimated to have the potential as a tumor intervention target colorectal cancer cells (HCT-8) and diagnostic marker for non-small-cell lung cancer. This article presents the mechanism of daunorubicin action and a method to improve the effectiveness of daunorubicin by modulating the activity of AKR1B10. Daunorubicin is an anthracycline antibiotic and antineoplastic agent. It acts by inhibiting cellular reproduction through interference with DNA replication although it may contribute to the induction of cell death by increasing oxidative stress through the generation of reactive oxygen species and free radicals. As an antineoplastic agent, daunorubicin carries significant toxicities including cytopenias, hepatotoxicity, and extravasation reactions. Like other anthracyclines, daunorubicin also exhibits cardiotoxicity in proportion with the cumulative dose received over time. Indications For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Daunorubicin is indicated in combination with [cytarabine] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. Daunorubicin is an anthracycline antibiotic that has antineoplastic activity and is used in the therapy of acute leukemia and AIDS-related Kaposi sarcoma. Cerubidine in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with other chemotherapy agents to treat the blastic phase of chronic myelogenous leukemia. DaunoXome is indicated as a first line cytotoxic therapy for advanced HIV-associated Kaposi’s sarcoma. DaunoXome is not recommended in patients with less than advanced HIV-related Kaposi’s sarcoma. Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia With Myelodysplasia-Related Changes Ewing’s Sarcoma Lymphoma, Diffuse Myeloblastic Leukemia Myeloid Leukemia, Chronic, Chronic Phase Non-Hodgkin’s Lymphoma (NHL) Therapy-Related Acute Myeloid Leukemia Wilms’ tumor Use in Cancer Daunorubicin hydrochloride is approved to be used with other drugs as remission induction therapy to treat: Acute lymphoblastic leukemia in adults and children. Acute myeloid leukemia in adults. It is also being studied in the treatment of other types of cancer. Contraindications are allergic to daunorubicin or any ingredients of this medication are breast-feeding have already been treated with the maximum allowable lifetime dose of any anthracycline drug (daunorubicin, doxorubicin, epirubicin, idarubicin) or mitoxantrone have heart failure have low blood cell counts caused by previous cancer drug treatment or radiation therapy are over the age of 75 a bacterial infection opportunistic fungal infection an infection due to a protozoa organism decreased function of bone marrow low levels of granulocytes, a type of white blood cell low levels of a type of white blood cell called neutrophils inflammation of the covering of the heart or pericardium cardiomyopathy, a disease of the heart muscle rapid ventricular heartbeat abnormal heart rhythm chronic heart failure inflammation of the middle tissue heart muscle liver problems seizures high amount of uric acid in the blood pregnancy a patient who is producing milk and breastfeeding kidney disease with likely reduction in kidney function an increased risk of developing an uncommon viral infection called an opportunistic infection Dosage Strengths: 20 mg; 5 mg/mL; 50 mg Acute Nonlymphocytic Leukemia Remission Induction in Combination: Under 60 years: 45 mg/m2 IV once daily on days 1, 2, and 3 of the first course and on days 1 and 2 of subsequent courses AND cytosine arabinoside (ara-C) 100 mg/m2 IV once daily for 7 days for the first course and 5 days for subsequent courses The attainment of a normal-appearing bone marrow may require up to 3 courses of induction. The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance. For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) in adults Acute Lymphocytic Leukemia Remission Induction in Combination: 45 mg/m2/day IV on days 1, 2, and 3 AND vincristine 2 mg IV on days 1, 8, and 15; prednisone 40 mg/m2/day orally on days 1 through 22, then tapered between days 22 to 29; L-asparaginase 500 IU/kg/day IV on days 22 through 32 The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance. Acute Nonlymphocytic Leukemia Remission Induction in Combination: 60 years and older: 30 mg/m2 IV once daily on days 1, 2, and 3 of the first course and on days 1 and 2 of subsequent courses AND cytosine arabinoside (ara-C) 100 mg/m2 IV once daily for 7 days for the first course and 5 days for subsequent courses Duration of therapy: The attainment of a normal-appearing bone marrow may require up to 3 courses of induction. The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance. This daunorubicin dose-reduction is based on a single study and may not be appropriate if optimal supportive care is availabl For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) in adults Pediatric Dose Acute Lymphocytic Leukemia Remission Induction in Pediatric Acute Lymphocytic Leukemia: In Combination: LESS THAN 2 YEARS OR LESS THAN 0.5 M2: 1 mg/kg IV on day 1 every week, vincristine 1.5 mg/m2 IV on day 1 every week, prednisone 40 mg/m2 orally daily; complete remission will usually be obtained within 4 courses of therapy; however, if after 4 courses the patient is in partial remission, an additional 1 or 2 courses may be given to obtain complete remission GREATER THAN 2 YEARS OR GREATER THAN 0.5 M2: 25 mg/m2 IV on day 1 every week, vincristine 1.5 mg/m2 IV on day 1 every week, prednisone 40 mg/m2 orally daily; complete remission will usually be obtained within 4 courses of therapy; however, if after 4 courses the patient is in partial remission, an additional 1 or 2 courses may be given to obtain complete remission The doses presented here are manufacturer suggested; consult local and institutional protocol for further guidance. Administration advice: This drug is for IV use only and should not be administered by intramuscular or subcutaneous routes, as severe tissue necrosis will result. This drug should be given into a rapidly flowing IV infusion of 0.9% sodium chloride or 5% dextrose injection. The tubing should be connected to a butterfly needle, inserted preferably into a large vein. The dose and the size of the vein will determine the rate of administration, which should not be less than 3 to 5 minutes. Erythematous streaking and facial flushing are indications of too rapid administration. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration. Side Effects The Most Common abdominal pain constipation darkening of soles, palms, or nails nausea vomiting sores in the mouth and throat diarrhea stomach pain hair loss red urine redness, pain, swelling, or burning at the site where the injection was given rash hives itching difficulty breathing or swallowing More Common diarrhea hot flashes nausea and vomiting reddish-coloured urine (not blood) – this is normal, and lasts 1 to 2 days after each dose difficulty breathing, swelling of your face, lips, tongue, or throat, chest pain, shortness of breath, sores in your mouth and throat, easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, yellowing of the skin or eyes (jaundice), and pain, burning, irritation, or skin changes where the injection was given Rare reduction in number of menstrual periods temporary total loss of hair (returns after treatments end) skin rash or itching sores in mouth and on lips black, tarry stools blood in urine cough or hoarseness with fever or chills fever or chills irregular heartbeat or palpitations in the chest lower back or side pain with fever or chills pain at injection site painful or difficult urination with fever or chills pinpoint red spots on skin shortness of breath or swelling of the lips, tongue, or face swelling of feet and lower legs unusual bleeding or bruising Interaction DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Daunorubicin. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Daunorubicin. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Daunorubicin. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Daunorubicin. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Daunorubicin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Daunorubicin. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daunorubicin. Afatinib Afatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Albendazole The metabolism of Albendazole can be decreased when combined with Daunorubicin. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daunorubicin. Alectinib The metabolism of Alectinib can be decreased when combined with Daunorubicin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin. Alfentanil The metabolism of Alfentanil can be increased when combined with Daunorubicin. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Daunorubicin. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Daunorubicin. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Daunorubicin. Alpelisib The metabolism of Alpelisib can be decreased when combined with Daunorubicin. Alprazolam The metabolism of Alprazolam can be decreased when combined with Daunorubicin. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Daunorubicin. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Daunorubicin. Ambrisentan The metabolism of Ambrisentan can be increased when combined with Daunorubicin. Aminophylline The metabolism of Aminophylline can be decreased when combined with Daunorubicin. Amiodarone The metabolism of Amiodarone can be decreased when combined with Daunorubicin. Amitriptyline The metabolism of Amitriptyline can be increased when combined with Daunorubicin. Amprenavir The metabolism of Amprenavir can be increased when combined with Daunorubicin. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Daunorubicin. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Daunorubicin. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Daunorubicin. Anastrozole The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Anastrozole. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Daunorubicin. Anifrolumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Daunorubicin. immune globulin The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daunorubicin. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Daunorubicin. Antilymphocyte The risk or severity of adverse effects can be increased when Daunorubicin is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Daunorubicin. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Daunorubicin. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin. Apalutamide Apalutamide may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. Apixaban The metabolism of Apixaban can be increased when combined with Daunorubicin. Apomorphine The metabolism of Apomorphine can be increased when combined with Daunorubicin. Apremilast The risk or severity of adverse effects can be increased when Daunorubicin is combined with Apremilast. Aprepitant The metabolism of Aprepitant can be increased when combined with Daunorubicin. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Daunorubicin. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Daunorubicin. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Daunorubicin. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Daunorubicin. Arsenic trioxide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide. Artemether The metabolism of Artemether can be increased when combined with Daunorubicin. Articaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Articaine. Astemizole The metabolism of Astemizole can be decreased when combined with Daunorubicin. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Daunorubicin. Asunaprevir The metabolism of Asunaprevir can be increased when combined with Daunorubicin. Atazanavir Daunorubicin may decrease the excretion rate of Atazanavir which could result in a higher serum level. Atenolol Atenolol may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Daunorubicin. Atropine Atropine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Avanafil Avanafil may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Avatrombopag Avatrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Axitinib The metabolism of Axitinib can be decreased when combined with Daunorubicin. Azacitidine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azacitidine. Azathioprine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azathioprine. Azelastine The metabolism of Azelastine can be increased when combined with Daunorubicin. Azithromycin The metabolism of Azithromycin can be decreased when combined with Daunorubicin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Daunorubicin. B live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Daunorubicin. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Daunorubicin. Baricitinib The risk or severity of adverse effects can be increased when Daunorubicin is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Daunorubicin. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Daunorubicin. Belantamab Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level. Belatacept The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belinostat. Belumosudil The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Daunorubicin. Bendamustine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Daunorubicin. Benzocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Daunorubicin. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Benzyl alcohol. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Daunorubicin. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Daunorubicin. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Daunorubicin. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Daunorubicin. Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Daunorubicin. Bimekizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bimekizumab. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Daunorubicin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin. Blinatumomab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Blinatumomab. Boceprevir The metabolism of Boceprevir can be increased when combined with Daunorubicin. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Daunorubicin. Bortezomib The metabolism of Bortezomib can be decreased when combined with Daunorubicin. Bosentan Bosentan may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Bosutinib The metabolism of Bosutinib can be decreased when combined with Daunorubicin. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin You Might Also Read Abatacept; Uses, Dosage, Side Effects, Drug Interactions Brigatinib The metabolism of Brigatinib can be decreased when combined with Daunorubicin. Brodalumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Brodalumab. Budesonide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Buspirone The metabolism of Buspirone can be increased when combined with Daunorubicin. Busulfan The metabolism of Busulfan can be decreased when combined with Daunorubicin. Butacaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Daunorubicin. Cabergoline The metabolism of Cabergoline can be decreased when combined with Daunorubicin. Caffeine Caffeine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Canakinumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Daunorubicin. Cannabidiol Cannabidiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Capecitabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Daunorubicin. Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Daunorubicin. Capsaicin The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Capsaicin. Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Daunorubicin. Carboplatin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin. Cefaclor Daunorubicin may decrease the excretion rate of Cefaclor which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Cenobamate The metabolism of Cenobamate can be increased when combined with Daunorubicin. Cephalexin The metabolism of Cephalexin can be decreased when combined with Daunorubicin. Ceritinib The metabolism of Ceritinib can be decreased when combined with Daunorubicin. Cerivastatin Cerivastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Certolizumab pegol The risk or severity of adverse effects can be increased when Daunorubicin is combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Daunorubicin. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Daunorubicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Chloroprocaine. Chloroquine The metabolism of Chloroquine can be increased when combined with Daunorubicin. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Daunorubicin. Chlorpheniramine The metabolism of Chlorpheniramine can be increased when combined with Daunorubicin. Chlorpromazine Chlorpromazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Cholesterol Cholesterol may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. Cholic Acid Cholic Acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Ciclesonide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ciclesonide. Cilostazol The metabolism of Cilostazol can be decreased when combined with Daunorubicin. Cimetidine Cimetidine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Cinchocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cinchocaine. Cisapride The metabolism of Cisapride can be decreased when combined with Daunorubicin. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Daunorubicin. Clarithromycin Daunorubicin may decrease the excretion rate of Clarithromycin which could result in a higher serum level. Clindamycin The metabolism of Clindamycin can be increased when combined with Daunorubicin. Clobetasol The risk or severity of adverse effects can be increased when Daunorubicin is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin. Clofazimine Clofazimine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Clomipramine The metabolism of Clomipramine can be decreased when combined with Daunorubicin. Clonidine The metabolism of Clonidine can be decreased when combined with Daunorubicin. Clopidogrel The metabolism of Clopidogrel can be increased when combined with Daunorubicin. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Clozapine The risk or severity of neutropenia can be increased when Daunorubicin is combined with Clozapine. Cobicistat Cobicistat may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Daunorubicin. Cocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Daunorubicin. Conivaptan The metabolism of Conivaptan can be decreased when combined with Daunorubicin. Copanlisib The metabolism of Copanlisib can be decreased when combined with Daunorubicin. Corticotropin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Daunorubicin is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Crizotinib The metabolism of Crizotinib can be decreased when combined with Daunorubicin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Daunorubicin. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Daunorubicin. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Daunorubicin. Cyclosporine Daunorubicin may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Daunorubicin. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Daunorubicin. Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Daunorubicin. Dabrafenib The metabolism of Dabrafenib can be decreased when combined with Daunorubicin. Dacarbazine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine. Daclatasvir Daclatasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Daunorubicin. Dactinomycin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Daunorubicin. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Daunorubicin. Dapsone The metabolism of Dapsone can be increased when combined with Daunorubicin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Daunorubicin. Darolutamide Darolutamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Dasabuvir Dasabuvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Dasatinib The metabolism of Dasatinib can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Decitabine. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Daunorubicin. Deflazacort The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin. Deoxycholic acid Deoxycholic acid may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Daunorubicin. Deslanoside Deslanoside may decrease the cardiotoxic activities of Daunorubicin. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Daunorubicin. Deucravacitinib The risk or severity of adverse effects can be increased when Daunorubicin is combined with Deucravacitinib. Deutetrabenazine The metabolism of Deutetrabenazine can be increased when combined with Daunorubicin. Dexamethasone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dexamethasone. Dexamethasone acetate Dexamethasone acetate may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Daunorubicin. Dextromethorphan The metabolism of Dextromethorphan can be increased when combined with Daunorubicin. Diazepam The metabolism of Diazepam can be increased when combined with Daunorubicin. Diclofenac Diclofenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Daunorubicin. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Difluocortolone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Daunorubicin. Digoxin Digoxin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Dihydroergocornine The metabolism of Dihydroergocornine can be decreased when combined with Daunorubicin. Dihydroergocristine Daunorubicin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level. Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Daunorubicin. Diltiazem The metabolism of Diltiazem can be increased when combined with Daunorubicin. Dimethyl fumarate The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Diphenhydramine. Dipyridamole Daunorubicin may decrease the excretion rate of Dipyridamole which could result in a higher serum level. Diroximel fumarate The risk or severity of adverse effects can be increased when Daunorubicin is combined with Diroximel fumarate. Disulfiram Daunorubicin may decrease the excretion rate of Disulfiram which could result in a higher serum level. Docetaxel The metabolism of Docetaxel can be decreased when combined with Daunorubicin. Dofetilide The metabolism of Dofetilide can be decreased when combined with Daunorubicin. Domperidone The metabolism of Domperidone can be increased when combined with Daunorubicin. Doravirine The metabolism of Doravirine can be increased when combined with Daunorubicin. Doxazosin The metabolism of Doxazosin can be decreased when combined with Daunorubicin. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Daunorubicin. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Daunorubicin. Dronedarone The metabolism of Dronedarone can be decreased when combined with Daunorubicin. Drospirenone The metabolism of Drospirenone can be decreased when combined with Daunorubicin. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Daunorubicin. Dutasteride The metabolism of Dutasteride can be increased when combined with Daunorubicin. Duvelisib The metabolism of Duvelisib can be decreased when combined with Daunorubicin. Dyclonine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Dyclonine. Ebastine The metabolism of Ebastine can be decreased when combined with Daunorubicin. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Daunorubicin. Eculizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Daunorubicin. Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Daunorubicin. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin. Efavirenz Efavirenz may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Elbasvir Elbasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Daunorubicin. Eliglustat The metabolism of Eliglustat can be decreased when combined with Daunorubicin. Eltrombopag Eltrombopag may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Emapalumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Emapalumab. Enasidenib The metabolism of Enasidenib can be decreased when combined with Daunorubicin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Daunorubicin. Entrectinib The metabolism of Entrectinib can be decreased when combined with Daunorubicin. Enzalutamide The serum concentration of Enzalutamide can be increased when it is combined with Daunorubicin. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Daunorubicin. Eplerenone The metabolism of Eplerenone can be increased when combined with Daunorubicin. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Daunorubicin. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Daunorubicin. Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Daunorubicin. Ergotamine The metabolism of Ergotamine can be decreased when combined with Daunorubicin. Eribulin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin. Erlotinib The metabolism of Erlotinib can be decreased when combined with Daunorubicin. Erythromycin Erythromycin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Daunorubicin. Estetrol The metabolism of Estetrol can be decreased when combined with Daunorubicin. Estradiol Estradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Estradiol benzoate Estradiol benzoate may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Estradiol cypionate Estradiol cypionate may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Estradiol dienanthate Estradiol dienanthate may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Estradiol valerate Estradiol valerate may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Estramustine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Daunorubicin. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Daunorubicin. Ethinylestradiol Ethinylestradiol may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Daunorubicin. Everolimus The metabolism of Everolimus can be decreased when combined with Daunorubicin. Ezetimibe Daunorubicin may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Daunorubicin. Febuxostat The excretion of Daunorubicin can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Felodipine Daunorubicin may decrease the excretion rate of Felodipine which could result in a higher serum level. Fenofibrate Daunorubicin may decrease the excretion rate of Fenofibrate which could result in a higher serum level. Fentanyl The metabolism of Fentanyl can be decreased when combined with Daunorubicin. Fexinidazole The metabolism of Fexinidazole can be increased when combined with Daunorubicin. Filgotinib The risk or severity of adverse effects can be increased when Daunorubicin is combined with Filgotinib. Finasteride The metabolism of Finasteride can be increased when combined with Daunorubicin. Finerenone The serum concentration of Finerenone can be increased when it is combined with Daunorubicin. Fingolimod Daunorubicin may increase the immunosuppressive activities of Fingolimod. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Daunorubicin. Flucloxacillin Flucloxacillin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Daunorubicin. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Daunorubicin. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Daunorubicin. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Daunorubicin. Fluocinonide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortolone. Fluorescein Fluorescein may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Daunorubicin. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Daunorubicin. Fluprednisolone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluprednisolone. Flutamide The metabolism of Flutamide can be increased when combined with Daunorubicin. Fluticasone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluticasone. You Might Also Read Dapsone 5% Tropical Gel - Uses, Dosage, Side Effects Fluvastatin The metabolism of Fluvastatin can be increased when combined with Daunorubicin. Fluvoxamine Fluvoxamine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Daunorubicin. Fosaprepitant The metabolism of Fosaprepitant can be decreased when combined with Daunorubicin. Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Daunorubicin. Fostamatinib Fostamatinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Fostemsavir Fostemsavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Fusidic acid Fusidic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Gallium nitrate The risk or severity of adverse effects can be increased when Daunorubicin is combined with Gallium nitrate. Gefitinib Gefitinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Daunorubicin. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin. Gilteritinib Gilteritinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Glasdegib Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Glatiramer The risk or severity of adverse effects can be increased when Daunorubicin is combined with Glatiramer. Glecaprevir Glecaprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Glimepiride Glimepiride may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Glipizide Daunorubicin may decrease the excretion rate of Glipizide which could result in a higher serum level. Glyburide Glyburide may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Glycyrrhizic acid Daunorubicin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Golimumab. Grazoprevir Grazoprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Guselkumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Daunorubicin. Halofantrine The metabolism of Halofantrine can be increased when combined with Daunorubicin. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Daunorubicin. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daunorubicin. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daunorubicin. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Daunorubicin. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Daunorubicin. Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Daunorubicin. Hydrocortisone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone acetate. Hydrocortisone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Hydrocortisone cypionate can be increased when combined with Daunorubicin. Hydrocortisone The metabolism of Hydrocortisone phosphate can be increased when combined with Daunorubicin. Hydrocortisone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Daunorubicin. Hydroxychloroquine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxychloroquine. Hydroxyprogesterone The metabolism of Hydroxyprogesterone caproate can be increased when combined with Daunorubicin. Hydroxyurea The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxyurea. Hydroxyzine The metabolism of Hydroxyzine can be increased when combined with Daunorubicin. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Daunorubicin. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Daunorubicin. Idarubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Idarubicin. Idelalisib The metabolism of Idelalisib can be decreased when combined with Daunorubicin. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Daunorubicin. Iloperidone The metabolism of Iloperidone can be decreased when combined with Daunorubicin. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Daunorubicin. Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Daunorubicin. Indinavir Indinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Indocyanine Daunorubicin may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Daunorubicin. Inebilizumab The risk or severity of infection can be increased when Daunorubicin is combined with Inebilizumab. Infigratinib The metabolism of Infigratinib can be decreased when combined with Daunorubicin. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Daunorubicin. Influenza The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Brisbane The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Daunorubicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Daunorubicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Influenza A virus A The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Influenza A virus The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Influenza B virus The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Influenza B The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Daunorubicin. Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daunorubicin. Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin. Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin. Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daunorubicin. Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin. Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin. Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daunorubicin. Irinotecan The metabolism of Irinotecan can be decreased when combined with Daunorubicin. Isavuconazole Isavuconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Isradipine Isradipine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Istradefylline Istradefylline may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Itraconazole Itraconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Ivacaftor The metabolism of Ivacaftor can be increased when combined with Daunorubicin. Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Daunorubicin. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Daunorubicin. Ixazomib The metabolism of Ixazomib can be decreased when combined with Daunorubicin. Ixekizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ixekizumab. COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Daunorubicin. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Daunorubicin. Ketoconazole Ketoconazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Lacosamide The metabolism of Lacosamide can be decreased when combined with Daunorubicin. Lansoprazole Lansoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Lapatinib The metabolism of Lapatinib can be increased when combined with Daunorubicin. Lasmiditan The serum concentration of Daunorubicin can be increased when it is combined with Lasmiditan. Ledipasvir Ledipasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Lefamulin The metabolism of Lefamulin can be decreased when combined with Daunorubicin. Leflunomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Leflunomide. Lemborexant The serum concentration of Lemborexant can be decreased when it is combined with Daunorubicin. Pantoprazole Pantoprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Paritaprevir Paritaprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Daunorubicin. Pazopanib The metabolism of Pazopanib can be decreased when combined with Daunorubicin. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin. Pegcetacoplan The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Daunorubicin. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Daunorubicin is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Daunorubicin. Penicillamine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Penicillamine. Pentamidine The metabolism of Pentamidine can be increased when combined with Daunorubicin. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Daunorubicin. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Daunorubicin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Daunorubicin. Perampanel The metabolism of Perampanel can be increased when combined with Daunorubicin. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Daunorubicin. Pertuzumab The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Pertuzumab. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Daunorubicin. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Daunorubicin. Phenobarbital Phenobarbital may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. Phenol The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Daunorubicin. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin. Phenytoin The metabolism of Phenytoin can be increased when combined with Daunorubicin. Pibrentasvir Pibrentasvir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Pimavanserin The metabolism of Pimavanserin can be decreased when combined with Daunorubicin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daunorubicin. Pimozide The metabolism of Pimozide can be decreased when combined with Daunorubicin. Pirfenidone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirfenidone. Pitavastatin Daunorubicin may decrease the excretion rate of Pitavastatin which could result in a higher serum level. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Daunorubicin. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Daunorubicin. Ponatinib The metabolism of Ponatinib can be decreased when combined with Daunorubicin. Ponesimod The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ponesimod. Pralatrexate The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate. Pralsetinib Pralsetinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Daunorubicin. Pravastatin Pravastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Praziquantel The metabolism of Praziquantel can be increased when combined with Daunorubicin. Prednisolone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednisolone. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Daunorubicin. Pretomanid The metabolism of Pretomanid can be decreased when combined with Daunorubicin. Prilocaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine. Progesterone Progesterone may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Propoxycaine. Propranolol The metabolism of Propranolol can be increased when combined with Daunorubicin. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Daunorubicin. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Daunorubicin. Prucalopride The metabolism of Prucalopride can be decreased when combined with Daunorubicin. Quetiapine The metabolism of Quetiapine can be increased when combined with Daunorubicin. Quinidine The metabolism of Quinidine can be decreased when combined with Daunorubicin. Quinine The metabolism of Quinine can be increased when combined with Daunorubicin. Rabeprazole Rabeprazole may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Rglobulin, human The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Daunorubicin. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daunorubicin. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Daunorubicin. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Daunorubicin. Ranolazine Ranolazine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Ravulizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ravulizumab. Regorafenib The metabolism of Regorafenib can be decreased when combined with Daunorubicin. Relugolix The metabolism of Relugolix can be increased when combined with Daunorubicin. Repaglinide Daunorubicin may decrease the excretion rate of Repaglinide which could result in a higher serum level. Reserpine Reserpine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Retapamulin The metabolism of Retapamulin can be decreased when combined with Daunorubicin. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Daunorubicin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Daunorubicin. Ribociclib The metabolism of Ribociclib can be decreased when combined with Daunorubicin. Rifampicin Rifampicin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Rilonacept The risk or severity of adverse effects can be increased when Daunorubicin is combined with Rilonacept. Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Daunorubicin. Rimegepant The metabolism of Rimegepant can be increased when combined with Daunorubicin. Ripretinib Ripretinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Risankizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Risankizumab. Risperidone The metabolism of Risperidone can be increased when combined with Daunorubicin. Ritonavir Ritonavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin. Rivaroxaban The metabolism of Rivaroxaban can be increased when combined with Daunorubicin. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Daunorubicin. Rolapitant Rolapitant may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Romidepsin The metabolism of Romidepsin can be decreased when combined with Daunorubicin. Ropeginterferon The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Ropivacaine. Rosiglitazone Rosiglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Rosuvastatin Daunorubicin may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Daunorubicin. Roxadustat The serum concentration of Daunorubicin can be increased when it is combined with Roxadustat. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Daunorubicin. Rucaparib Rucaparib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Daunorubicin. Safinamide Safinamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Salmeterol The metabolism of Salmeterol can be increased when combined with Daunorubicin. You Might Also Read Is Naproxen Is Pregnancy Safe, Dosage, Warning Saquinavir Saquinavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Satralizumab. Saxagliptin The metabolism of Saxagliptin can be increased when combined with Daunorubicin. Secukinumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Secukinumab. Selpercatinib The serum concentration of Selpercatinib can be decreased when it is combined with Daunorubicin. Selumetinib The metabolism of Selumetinib can be increased when combined with Daunorubicin. Sildenafil The metabolism of Sildenafil can be increased when combined with Daunorubicin. Siltuximab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Siltuximab. Simeprevir Simeprevir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Simvastatin Simvastatin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Siponimod The metabolism of Siponimod can be decreased when combined with Daunorubicin. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daunorubicin. Sirolimus The metabolism of Sirolimus can be decreased when combined with Daunorubicin. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Daunorubicin. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Daunorubicin. Sonidegib The metabolism of Sonidegib can be decreased when combined with Daunorubicin. Sorafenib The metabolism of Sorafenib can be decreased when combined with Daunorubicin. Sotagliflozin Sotagliflozin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Spesolimab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Spesolimab. Spironolactone Spironolactone may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Stiripentol The excretion of Daunorubicin can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Daunorubicin. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Daunorubicin. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Daunorubicin. Sulfasalazine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sulfasalazine. Sulfinpyrazone Daunorubicin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Daunorubicin. Sunitinib The metabolism of Sunitinib can be decreased when combined with Daunorubicin. Suvorexant The metabolism of Suvorexant can be decreased when combined with Daunorubicin. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Daunorubicin. Tadalafil The metabolism of Tadalafil can be increased when combined with Daunorubicin. Tafamidis The serum concentration of Daunorubicin can be increased when it is combined with Tafamidis. Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Daunorubicin. Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Daunorubicin. Taurocholic acid Taurocholic acid may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy. Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Daunorubicin. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Daunorubicin is combined with Tedizolid phosphate. Tegafur The metabolism of Tegafur can be increased when combined with Daunorubicin. Telaprevir The metabolism of Telaprevir can be increased when combined with Daunorubicin. Telithromycin The metabolism of Telithromycin can be increased when combined with Daunorubicin. Telmisartan Telmisartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Temozolomide. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Daunorubicin. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Daunorubicin. Teniposide The metabolism of Teniposide can be decreased when combined with Daunorubicin. Tenofovir The metabolism of Tenofovir alafenamide can be decreased when combined with Daunorubicin. Tepotinib Tepotinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Teprotumumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teprotumumab. Terfenadine Terfenadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Teriflunomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide. Testosterone The metabolism of Testosterone can be increased when combined with Daunorubicin. Testosterone cypionate The metabolism of Testosterone cypionate can be increased when combined with Daunorubicin. Testosterone enanthate The metabolism of Testosterone enanthate can be increased when combined with Daunorubicin. Tetracaine The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Tetracaine. Tezacaftor The metabolism of Tezacaftor can be increased when combined with Daunorubicin. Thalidomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Thalidomide. Theophylline The metabolism of Theophylline can be decreased when combined with Daunorubicin. Thiotepa The metabolism of Thiotepa can be decreased when combined with Daunorubicin. Ticagrelor The metabolism of Ticagrelor can be increased when combined with Daunorubicin. Tick-borne The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Daunorubicin. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Daunorubicin. Tinidazole Daunorubicin may decrease the excretion rate of Tinidazole which could result in a higher serum level. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Daunorubicin. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Daunorubicin. Tipranavir Tipranavir may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Daunorubicin. Tivozanib Tivozanib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tixocortol. Tocilizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tocilizumab. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Daunorubicin. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Daunorubicin. Topotecan The risk or severity of adverse effects can be increased when Daunorubicin is combined with Topotecan. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Daunorubicin. Trabectedin The metabolism of Trabectedin can be decreased when combined with Daunorubicin. Tramadol The metabolism of Tramadol can be decreased when combined with Daunorubicin. Trastuzumab The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Daunorubicin. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Daunorubicin. Trazodone The metabolism of Trazodone can be increased when combined with Daunorubicin. Tretinoin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Tretinoin. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Daunorubicin. Triazolam The metabolism of Triazolam can be increased when combined with Daunorubicin. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Daunorubicin. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Daunorubicin. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Daunorubicin. Trilostane The risk or severity of adverse effects can be increased when Daunorubicin is combined with Trilostane. Troglitazone Troglitazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daunorubicin. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Daunorubicin. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Daunorubicin. Udenafil The metabolism of Udenafil can be increased when combined with Daunorubicin. Upadacitinib The risk or severity of adverse effects can be increased when Daunorubicin is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Daunorubicin. Ursodeoxycholic acid Ursodeoxycholic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level. Valbenazine The metabolism of Valbenazine can be increased when combined with Daunorubicin. Vandetanib The metabolism of Vandetanib can be decreased when combined with Daunorubicin. Vardenafil The metabolism of Vardenafil can be decreased when combined with Daunorubicin. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Daunorubicin. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Daunorubicin. Vedolizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vedolizumab. Pregnancy and Lactation Pregnancy Category D Pregnancy There is a possibility of birth defect if either the man or woman is using daunorubicin at the time of conception, or if it is taken during pregnancy. Effective birth control should be practiced while using this medication. This medication may harm the baby if used during pregnancy. Tell your doctor immediately if you become pregnant while using this medication. Lactation It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Cerubidine (daunorubicin) , mothers should be advised to discontinue nursing during Cerubidine therapy. How should this medicine be used? Daunorubicin comes as a solution (liquid) or as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility along with other chemotherapy medications. When daunorubicin is used to treat AML, it is usually injected once a day on certain days of your treatment period. When daunorubicin is used to treat ALL, it is usually injected once a week. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before receiving daunorubicin injection, tell your doctor and pharmacist if you are allergic to daunorubicin, any other medications, or any of the ingredients in daunorubicin injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: azathioprine (Imuran), cyclosporine (Neoral, Sandimmune), methotrexate (Rheumatrex, Trexall), sirolimus (Rapamune), and tacrolimus (Prograf). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Other medications may also interact with daunorubicin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor if you have or have ever had any medical condition. tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You should not become pregnant while you are receiving daunorubicin injection. If you become pregnant while receiving daunorubicin, call your doctor. Daunorubicin may harm the fetus. References https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochloride https://pubchem.ncbi.nlm.nih.gov/compound/Daunorubicin https://pubchem.ncbi.nlm.nih.gov/compound/Daunorubicin-hydrochloride https://www.drugs.com/mtm/daunorubicin.html https://www.ncbi.nlm.nih.gov/books/NBK559073/ https://www.webmd.com/drugs/2/drug-5021/daunorubicin-intravenous/details/list-contraindications https://rxharun.com/rxharun/daunorubicin-uses-dosage-side-effects-interactions/#gsc.tab=0 https://en.wikipedia.org/wiki/Daunorubicin https://medlineplus.gov/druginfo/meds/a682289.html https://go.drugbank.com/drugs/DB00694 ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL178/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D003630 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/DAUNORUBICIN DrugBank https://www.drugbank.ca/legal/terms_of_use Daunorubicin https://www.drugbank.ca/drugs/DB00694 Therapeutic Target Database (TTD) Daunorubicin http://idrblab.net/ttd/data/drug/details/D01XWG CAMEO Chemicals https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false DAUNOMYCIN https://cameochemicals.noaa.gov/chemical/16190 CAMEO Chemical Reactivity Classification https://cameochemicals.noaa.gov/browse/react CAS Common Chemistry https://creativecommons.org/licenses/by-nc/4.0/ Daunorubicin https://commonchemistry.cas.org/detail?cas_rn=20830-81-3 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Daunorubicin [INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0020830813 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DTP/NCI https://www.cancer.gov/policies/copyright-reuse daunorubicin https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=756717 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Daunorubicin https://comptox.epa.gov/dashboard/DTXSID7022883 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Daunorubicin https://echa.europa.eu/substance-information/-/substanceinfo/100.040.048 Daunorubicin https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/94957 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking DAUNORUBICIN https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ZS7284E0ZP Hazardous Substances Data Bank (HSDB) DAUNORUBICIN https://pubchem.ncbi.nlm.nih.gov/source/hsdb/5095 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Daunorubicin http://www.hmdb.ca/metabolites/HMDB0014832 HMDB0014832_msms_2233133 https://hmdb.ca/metabolites/HMDB0014832#spectra Haz-Map, Information on Hazardous Chemicals and Occupational Diseases https://haz-map.com/About Daunomycin https://haz-map.com/Agents/2026 ChEBI Daunorubicin http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:41977 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking DAUNORUBICIN https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Daunorubicin https://www.ncbi.nlm.nih.gov/books/n/livertox/Daunorubicin/ LOTUS – the natural products occurrence database https://lotus.nprod.net/ LOTUS Tree https://lotus.naturalproducts.net/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62091 NCI Thesaurus Tree https://ncit.nci.nih.gov CCSbase https://ccsbase.net/ ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html CYTARABINE; DAUNORUBICIN https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CYTARABINE;+DAUNORUBICIN DAUNORUBICIN https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DAUNORUBICIN Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking daunorubicin https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/866161 https://pubchem.ncbi.nlm.nih.gov/substance/24769892 https://pubchem.ncbi.nlm.nih.gov/substance/375991195 EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking Patent:7850990 https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book LIPID MAPS Daunorubicin https://lipidmaps.org/databases/lmsd/LMPK13050002 Lipid Classification https://www.lipidmaps.org/ International Agency for Research on Cancer (IARC) https://publications.iarc.fr/Terms-Of-Use Daunomycin https://monographs.iarc.who.int/list-of-classifications IARC Classification https://www.iarc.fr/ MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license DAUNORUBICIN https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22STQGQHZAVUOBTE-VGBVRHCVSA-N%22%27 National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking DAUNORUBICIN https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Cerubidine (Daunorubicin Hydrochloride) https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochloride NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html daunorubicin https://rxnav.nlm.nih.gov/id/rxnorm/3109 NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DM1 PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ SpectraBase DAUNOMYCIN https://spectrabase.com/spectrum/3VW4DwufjFT https://spectrabase.com/spectrum/KyvBXEaNjqC Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=38061049-802281767 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=38061049-802269208 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Daunorubicin https://list.essentialmeds.org/medicines/85 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Daunorubicin https://www.wikidata.org/wiki/Q411659 Wiley https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=125302 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Daunorubicin https://www.ncbi.nlm.nih.gov/mesh/68003630 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antibiotics, Antineoplastic https://www.ncbi.nlm.nih.gov/mesh/68000903 Topoisomerase II Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68059005 KEGG https://www.kegg.jp/kegg/legal.html Lipids http://www.genome.jp/kegg-bin/get_htext?br08002.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 390638707 https://pubchem.ncbi.nlm.nih.gov/substance/390638707 SID 403391290 https://pubchem.ncbi.nlm.nih.gov/substance/403391290 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More